Research Innovation Spotlight on Small Molecule Oncology - January 23, 2024
This is an exclusive invite-only opportunity for selected industry professionals (corporate representatives and venture investors) to attend our virtual Research Innovation Spotlight on Small Molecule Oncology featuring engaging presentations followed by moderated audience Q&A from four leading researchers based in Southern California.
You will learn about current research from principle investigators who are working on breakthroughs that would benefit from relationships with industry and/or additional investment in the research. This is a unique opportunity to see early advances before they are commercialized.
Presenting Researchers
Dr. Matthew Rettig, M.D.; Medical Director, Prostate Cancer Program of the Institute of Urologic Oncology at UCLA (profile).
Research presenting: analogs of JN103 that have similar in vitro performance as JN103 with improved PK, which we have already partially demonstrated to be the case with one of our analogs (JN185).
-----
Dr. Wendong Huang, Ph.D.; Professor, Beckman Research Institute of City of Hope; Adjunct Professor of USC Keck Medical School; Professor, Department of Diabetes Complications & Metabolism at City of Hope (profile).
Research presenting: a promising clinical strategy to treat lymphoma and other Myc-positive tumors with development of a potent berbamine derivative compound which selectively targets CamkII kinase.
-----
Dr. Mohan Kaadige, Ph.D.; Research Associate Professor, Applied Cancer Research and Drug Discovery Translational Genomics Research Institute, part of City of Hope (profile).
Research presenting: findings from our preclinical investigation of TGN-1062, a dual CDK7 and FLT3 inhibitor which shows potent anti-AML activity and synergizes with Venetoclax
-----
Dr. Jean Shih, Ph.D.; Boyd & Elsie Welin Professor, Pharmacology and Pharmaceutical Sciences at USC (profile).
Research presenting: NMI, a near-infrared MAO-A inhibitor, is a potent dual-action theranostic molecule enabling non-invasive diagnosis and treatment of brain, prostate, and colon cancers, with added utility for tumor margin visualization during surgery.
-----
Event Moderator: Chris LeMasters, CEO at XinThera, a Gilead Company (profile)
XinThera, Inc., a privately held biotechnology company focused on small molecule discovery and development of oncology and immunology therapeutics.
Program Format
• Virtual live presentations of 4 research projects
• Each project lead gets up to 10 minutes to present their research followed by moderated attendee Q&A for the remainder of their time (a total of 20 minutes per presenter).
Agenda
10:00 AM Welcome & Attendee Introductions
10:15 AM Presentations and moderated Q&A
11:45 AM Program Concludes
Why You Should Attend
• Better understand compelling innovations emerging from SoCal's finest research institutions
• See multiple solutions and technologies from a variety of geographies in one virtual session
• Interact directly with the primary investigators to discuss potential future applications and build valuable relationships
For our Life Sciences spotlight series, the Alliance has partnered with BioscienceLA who bring an abundance of subject matter and industry experience. In addition, we are grateful to Foresite Capital for underwriting the series and providing additional expertise and guidance.
Previous Spotlights and more program information can be found on our website.